Avacta Group PLC - Completion of Placing and TVR

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Completion of Placing and TVR

LONDON and PHILADELPHIA - November 3, 2025 - Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION^®, a tumor-activated oncology delivery platform, today confirms that following Admission earlier today of the 25,396,806 Placing Shares, the Amendments to the Convertible Bond as set out in the Placing Announcement have taken effect.

The Company's enlarged issued ordinary share capital is 436,445,681 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Capitalized terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the Placing Announcement issued on 20 October 2025.

-Ends-

For further information from Avacta, please contact:

About Avacta - www.avacta.com

Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION^®. The pre|CISION^® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.

About pre|CISION^®

The key aspect of pre|CISION^® is its peptide drug conjugates (PDC) technology.  The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION^® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION^® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.